Active substance
Results for the substance palbociclib
6 results
About this active substance
Palbociclib is a cyclin-dependent kinase (CDK4/6) inhibitor used in the treatment of advanced or metastatic breast cancer that is hormone receptor-positive (HR+) and HER2-negative. It works by inhibiting the cell cycle, preventing tumor cell proliferation.
The medication is administered orally, as directed by a doctor, usually once daily for 21 days followed by a 7-day break. It is important for patients to follow the treatment regimen and undergo regular tests to monitor blood cell counts.
Patients should be aware of potential side effects, such as fatigue, nausea, or neutropenia. It is important to inform the doctor of any unusual symptoms.
Common side effects include fatigue, nausea, and neutropenia. In rare cases, severe reactions such as serious infections or liver toxicity may occur. Patients should be informed of these risks before use.
The medication is administered orally, as directed by a doctor, usually once daily for 21 days followed by a 7-day break. It is important for patients to follow the treatment regimen and undergo regular tests to monitor blood cell counts.
Patients should be aware of potential side effects, such as fatigue, nausea, or neutropenia. It is important to inform the doctor of any unusual symptoms.
Common side effects include fatigue, nausea, and neutropenia. In rare cases, severe reactions such as serious infections or liver toxicity may occur. Patients should be informed of these risks before use.
-
-
IBRANCE 100mg capsules PFIZER ORIGINAL MEDICINE
-
IBRANCE 75mg capsules PFIZER ORIGINAL MEDICINE
-
IBRANCE 100mg film-coated tablets PFIZER ORIGINAL MEDICINE
-
IBRANCE 75mg film-coated tablets PFIZER ORIGINAL MEDICINE
-
IBRANCE 125mg film-coated tablets PFIZER ORIGINAL MEDICINE